RxDoctor Payments Data

Confidence Alaboson

Nurse Practitioner · Houston, TXNPI 1750954970

Payments from drug & device makers

$12,703in general payments, 2019–2025

Across 461 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novartis$981
  • Johnson & Johnson$912
  • Merck$755
  • Lilly USA, LLC$709
  • E.r. Squibb & Sons, L.L.C.$601
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$2252%
  • Food & beverage$11,24289%
  • Education$1,1369%
  • Other$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)36$1,045
Novartis39$981
Johnson & Johnson27$912
Merck31$755
Lilly USA, LLC26$709
E.r. Squibb & Sons, L.L.C.15$601
Seagen Inc.8$510
Bristol Myers Squibb19$505
Incyte Corporation15$439
Eisai Inc.19$439
Pharmacyclics LLC, An Abbvie Company13$409
GSK17$402
AbbVie16$334
Sobi, Inc10$319
Takeda Pharmaceuticals U.S.A., Inc.13$311
Daiichi Sankyo Inc.13$307
Astellas Pharma US Inc8$278
Bayer10$217
Genentech USA, Inc.9$206
Pfizer7$150
Sanofi5$145
Exelixis Inc.4$137
Rigel Pharmaceuticals, Inc.5$136
Stemline Therapeutics Inc.3$133
Pharmaessentia USA Corporation6$132
Pharmacosmos Therapeutics Inc.5$129
Myriad Genetic Laboratories, Inc.1$115
Deciphera Pharmaceuticals Inc.4$114
Ipsen Biopharmaceuticals, Inc4$107
Apellis Pharmaceuticals, Inc.4$107
Janssen Scientific Affairs, LLC1$106
Regeneron Healthcare Solutions, Inc.4$98
Taiho Oncology, Inc.5$93
Kyowa Kirin, Inc.4$91
ADC Therapeutics America, Inc.4$90
Adaptive Biotechnologies Corporation4$87
Tersera Therapeutics LLC3$84
CTI Biopharma Corp.3$82
AVEO Pharmaceuticals, Inc.3$73
G1 Therapeutics, Inc.3$62
Morphosys, US Inc.3$58
Beone Medicines USA, Inc.2$51
Syndax Pharmaceuticals, Inc.2$50
Puma Biotechnology, Inc.2$49
Recordati_rare_diseases_inc.2$49
Spectrum Pharmaceuticals Inc.2$48
Blueprint Medicines Corporation2$47
Agios Pharmaceuticals, Inc.2$46
Amneal Pharmaceuticals LLC2$41
Mirati Therapeutics, Inc.2$35
Immunocore Limited1$33
Jazz Pharmaceuticals Inc.1$31
Immunogen, Inc.2$28
Array Biopharma Inc1$27
Sumitomo Pharma America, Inc.1$25
Geron Corporation1$21
Azurity Pharmaceuticals, Inc.1$20
EMD Serono, Inc.1$20
Iovance Biotherapeutics, Inc.1$20
Genmab U.S., Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,703 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$6,168
Medicare patients
49
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocortisone11$244
Tramadol Hcl11$103

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →